Stattic

For research use only. Not for use in humans.

目录号：S7024

CAS No. 19983-44-9

Stattic 是第一个非肽类STAT3小分子抑制剂，有效抑制STAT3激活和核易位，IC50为5.1 μM，其作用于STAT3的选择性远高于STAT1。Stattic 可诱导凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 730.64	现货
25mg	RMB 901.23	现货
50mg	RMB 1392.12	现货
100mg	RMB 2375.1	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Stattic发表文献153篇：

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Metab, 2020, 31(2):327-338

PubMed: 31928884 ( click the link to review the publication )

Nat Med, 2018, 24(5):563-571

PubMed: 29713085 ( click the link to review the publication )

Cell, 2017, 7;170(6):1134-1148.e10.

PubMed: 28886382 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-021-01768-8

PubMed: 33824475 ( click the link to review the publication )

Cancer Lett, 2021, 513:36-49

PubMed: 33991616 ( click the link to review the publication )

Breast Cancer Res, 2021, 23(1):35

PubMed: 33736709 ( click the link to review the publication )

Front Immunol, 2021, 12:630196

PubMed: 33897686 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:631163

PubMed: 33937232 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(3):3443-3458

PubMed: 33428604 ( click the link to review the publication )

Oncogenesis, 2021, 10(1):8

PubMed: 33431808 ( click the link to review the publication )

Transl Psychiatry, 2021, 11(1):298

PubMed: 34016951 ( click the link to review the publication )

Ecotoxicol Environ Saf, 2021, 208:111693

PubMed: 33396024 ( click the link to review the publication )

Genes Brain Behav, 2021, e12729

PubMed: 33641239 ( click the link to review the publication )

Phytother Res, 2021, 10.1002/ptr.7117

PubMed: 34038010 ( click the link to review the publication )

Prostate, 2021, 81(8):452-462

PubMed: 33822400 ( click the link to review the publication )

PLoS Pathog, 2021, 17(2):e1009303

PubMed: 33529218 ( click the link to review the publication )

Cell Rep, 2020, 30(3):793-806

PubMed: 31968254 ( click the link to review the publication )

Elife, 2020, 30;9. pii: e51317

PubMed: 32223889 ( click the link to review the publication )

J Hematol Oncol, 2020, 5;13(1):68

PubMed: 32503584 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32045997 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32150944 ( click the link to review the publication )

Cell Death Discov, 2020, 2;6:42

PubMed: 32528731 ( click the link to review the publication )

J Mol Cell Biol, 2020, 1 pii: mjaa011

PubMed: 32236560 ( click the link to review the publication )
Stem Cell Res Ther, 2020, 11(1):505

PubMed: 33246502 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:6584059

PubMed: 33274004 ( click the link to review the publication )

Oxid Med Cell Longev, 2020,

PubMed: 32855767 ( click the link to review the publication )

J Am Heart Assoc, 2020, 9(18):e017071

PubMed: 32865099 ( click the link to review the publication )

Front Oncol, 2020, 5;10:652

PubMed: 32432040 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15563

PubMed: 32618105 ( click the link to review the publication )

Biochem Pharmacol, 2020, S0006-2952(20)30632-8

PubMed: 33359364 ( click the link to review the publication )

Cancer Immunol Immunother, 2020, 69(1):115-126

PubMed: 31802182 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32823915 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32046095 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:405

PubMed: 32863764 ( click the link to review the publication )

Cell Mol Neurobiol, 2020, 18

PubMed: 32424774 ( click the link to review the publication )

Invest New Drugs, 2020, 20

PubMed: 32436058 ( click the link to review the publication )

Life Sci, 2020, 242:117221

PubMed: 31881224 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

PLoS One, 2020, 15(11):e0242337

PubMed: 33180876 ( click the link to review the publication )

Int J Oral Sci, 2020, 12(1):38

PubMed: 33380723 ( click the link to review the publication )

Hum Exp Toxicol, 2020, 39(2):224-234

PubMed: 31610697 ( click the link to review the publication )

Exp Clin Endocrinol Diabetes, 2020, 10.1055/a-0998-7985

PubMed: 31896157 ( click the link to review the publication )

Pharmacol Res, 2020, 153:104661

PubMed: 31982491 ( click the link to review the publication )

J Cell Physiol, 2020, 235(2):1076-1089

PubMed: 31276203 ( click the link to review the publication )

Cell Signal, 2020, 65:109413

PubMed: 31494257 ( click the link to review the publication )

FASEB Bioadv, 2020, 2(2):116-125

PubMed: 32123861 ( click the link to review the publication )

Front Immunol, 2020, 11:2031

PubMed: 33042115 ( click the link to review the publication )
J Invest Dermatol, 2020, S0022-202X(20)31981-3

PubMed: 32805217 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, S2352-345X(20)30190-9

PubMed: 33238220 ( click the link to review the publication )

Oncotarget, 2020, 11(33):3129-3143

PubMed: 32913557 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106143

PubMed: 32062080 ( click the link to review the publication )

Cell Death Dis, 2020, 11(7):531

PubMed: 32661236 ( click the link to review the publication )

Nat Commun, 2019, 10(1):716

PubMed: 30755611 ( click the link to review the publication )

Biomaterials, 2019, 219:119371

PubMed: 31352310 ( click the link to review the publication )

Mol Cancer, 2019, 18(1):40

PubMed: 30866952 ( click the link to review the publication )

Diabetes, 2019, 68(6):1303-1314

PubMed: 30936144 ( click the link to review the publication )

Redox Biol, 2019, 24:101189

PubMed: 30986607 ( click the link to review the publication )

Redox Biol, 2019, 20:451-457

PubMed: 30439686 ( click the link to review the publication )

Brain Behav Immun, 2019, 81:228-246

PubMed: 31207335 ( click the link to review the publication )

J Pathol, 2019, 248(4):438-451

PubMed: 30900255 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):322

PubMed: 31331377 ( click the link to review the publication )

EBioMedicine, 2019, 39:132-144

PubMed: 30528455 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)E1939

PubMed: 31817171 ( click the link to review the publication )

Ther Adv Med Oncol, 2019, 11:1758835919846806

PubMed: 31205504 ( click the link to review the publication )

Cell Biol Toxicol, 2019, 10.1007/s10565-019-09471-x

PubMed: 30941654 ( click the link to review the publication )

Kidney Blood Press Res, 2019, 44(6):1453-1464

PubMed: 31722339 ( click the link to review the publication )

Oncogenesis, 2019, 8(8):39

PubMed: 31311917 ( click the link to review the publication )

Front Oncol, 2019,

PubMed: 31019895 ( click the link to review the publication )

J Virol, 2019, 93(9)

PubMed: 30787154 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31575039 ( click the link to review the publication )

J Clin Periodontol, 2019, 10.1111/jcpe.13166

PubMed: 31286538 ( click the link to review the publication )
Respir Res, 2019, 20(1):184

PubMed: 31416461 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:1309-1319

PubMed: 30804683 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 380:114698

PubMed: 31394157 ( click the link to review the publication )

Cytokine, 2019, 119:81-89

PubMed: 30903867 ( click the link to review the publication )

J Cell Biochem, 2019, 120(4):5315-5325

PubMed: 30320916 ( click the link to review the publication )

Neuroscience, 2019, 416:198-206

PubMed: 31374230 ( click the link to review the publication )

Int J Oncol, 2019, 10.3892/ijo.2019.4880

PubMed: 31545422 ( click the link to review the publication )

Cancer Med, 2019, 8(17):7345-7358

PubMed: 31631559 ( click the link to review the publication )

Mol Immunol, 2019, 111:162-171

PubMed: 31063937 ( click the link to review the publication )

Oncol Rep, 2019, 41(1):437-446

PubMed: 30365081 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:1137-1146

PubMed: 30809095 ( click the link to review the publication )

Scand J Immunol, 2019, 89(6):e12761

PubMed: 30977163 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2019, 2019:3909468

PubMed: 31485245 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3803-3808

PubMed: 31262907 ( click the link to review the publication )

Pathol Res Pract, 2019, 215(6):152392

PubMed: 30922625 ( click the link to review the publication )

Am J Nucl Med Mol Imaging, 2019,

PubMed: 31976162 ( click the link to review the publication )

Immunity, 2018, 48(4):787-798

PubMed: 29653697 ( click the link to review the publication )

Circulation, 2018, 30;138(18):2021-2035

PubMed: 29967195 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1523

PubMed: 29670076 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6236-6247

PubMed: 30131384 ( click the link to review the publication )

Blood Cancer J, 2018, 8(2):20

PubMed: 29440639 ( click the link to review the publication )

Cancer Lett, 2018, 436:52-62

PubMed: 30118844 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):375

PubMed: 29515107 ( click the link to review the publication )

Front Immunol, 2018,

PubMed: 29867938 ( click the link to review the publication )
Mol Oncol, 2018, 12(7):1203-1215

PubMed: 29791786 ( click the link to review the publication )

Carcinogenesis, 2018, 39(9):1165-1175

PubMed: 29893810 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(3):489-501

PubMed: 29637003 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(11):1057-1064

PubMed: 30277836 ( click the link to review the publication )

Cell Cycle, 2018, 17(4):428-438

PubMed: 29468929 ( click the link to review the publication )

Int Immunopharmacol, 2018, 58:136-144

PubMed: 29587202 ( click the link to review the publication )

Transl Oncol, 2018, 11(2):487-497

PubMed: 29494948 ( click the link to review the publication )

Int J Mol Med, 2018, 42(1):497-504

PubMed: 29620257 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2018, 22(19):6308-6314

PubMed: 30338828 ( click the link to review the publication )

Scand J Immunol, 2018, 88(3):e12703

PubMed: 30047999 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):370-380

PubMed: 29471502 ( click the link to review the publication )

Tumour Biol, 2018, 40(1):1010428317731369

PubMed: 29320977 ( click the link to review the publication )

Circ Res, 2017, 121(6):617-627

PubMed: 28743805 ( click the link to review the publication )

Mol Ther Oncolytics, 2017, 6:90-99

PubMed: 28875159 ( click the link to review the publication )

Cell Death Dis, 2017, 8(4):e2725

PubMed: 28383559 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

J Mol Med (Berl), 2017, 95(2):221-233

PubMed: 27709266 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(3):433-447

PubMed: 28401002 ( click the link to review the publication )

Biochem Pharmacol, 2017, 136:40-50

PubMed: 28404378 ( click the link to review the publication )

Sci Rep, 2017, 7(1):11540

PubMed: 28912535 ( click the link to review the publication )

Am J Pathol, 2017, 187(5):980-986

PubMed: 28284718 ( click the link to review the publication )

Cell Signal, 2017, 32:48-58

PubMed: 28093267 ( click the link to review the publication )

Toxicol In Vitro, 2017, 45(Pt 1):10-18

PubMed: 28739487 ( click the link to review the publication )

PLoS One, 2017, 12(6):e0178844

PubMed: 28636670 ( click the link to review the publication )
Gene, 2017, 627:114-122

PubMed: 28603075 ( click the link to review the publication )

Mol Med Rep, 2017, 16(6):9111-9119

PubMed: 28990062 ( click the link to review the publication )

Int J Clin Exp Pathol, 2017, 10(7):7466-7474

PubMed: 31966590 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13174-13185

PubMed: 28061458 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29100353 ( click the link to review the publication )

Sci Rep, 2017, 10.1038/srep41404

PubMed: 28112250 ( click the link to review the publication )

Oncotarget, 2017, 8(37):61876-61889

PubMed: 28977911 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31227-31237

PubMed: 28415722 ( click the link to review the publication )

Leukemia, 2016, 30(6):1311-9

PubMed: 26854024 ( click the link to review the publication )

Cell Rep, 2016, 15(3):460-470

PubMed: 27068459 ( click the link to review the publication )

EBioMedicine, 2016, 8:132-149

PubMed: 27428425 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2294

PubMed: 27415424 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1863(7 Pt A):1579-88

PubMed: 27066979 ( click the link to review the publication )

Int J Cardiol, 2016, 210:85-92

PubMed: 26930642 ( click the link to review the publication )

Cancer Prev Res (Phila), 2016, 9(8):657-63

PubMed: 27267892 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2010-2023

PubMed: 26663388 ( click the link to review the publication )

Int J Oncol, 2016, 48(1):161-72

PubMed: 26549725 ( click the link to review the publication )

J Physiol Sci, 2016, 66(3):229-39

PubMed: 26541157 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Antioxid Redox Signal, 2015, 24(2):70-83

PubMed: 26154696 ( click the link to review the publication )

Neoplasia, 2015, 17(7):586-97

PubMed: 26297436 ( click the link to review the publication )

Transl Res, 2015, 166(4):384-98

PubMed: 25843671 ( click the link to review the publication )

Hum Pathol, 2015, 46(2):284-94

PubMed: 25537973 ( click the link to review the publication )

FEBS Lett, 2015, 589(1):52-8

PubMed: 25436422 ( click the link to review the publication )
FEBS Lett, 2015, 589(1):52-8

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(5):e0128406

PubMed: 26010889 ( click the link to review the publication )

J Interferon Cytokine Res, 2015, 10.1089/jir.2014.0128

PubMed: 25919795 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43992-4004

PubMed: 26556857 ( click the link to review the publication )

Tumour Biol, 2015, 10.1007/s13277-015-3681-y

PubMed: 26124007 ( click the link to review the publication )

Oncotarget, 2015, 6(10):8244-54

PubMed: 25749519 ( click the link to review the publication )

J Exp Med, 2015, 212(12):2147-63

PubMed: 26552708 ( click the link to review the publication )

Tumour Biol, 2015, 36(12):9475-86

PubMed: 26124007 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

产品安全说明书

STAT抑制剂选择性比较

生物活性

产品描述

Stattic 是第一个非肽类STAT3小分子抑制剂，有效抑制STAT3激活和核易位，IC50为5.1 μM，其作用于STAT3的选择性远高于STAT1。Stattic 可诱导凋亡。

特性

Stattic是第一个非肽类小分子，抑制STAT3 SH2结构域的功能，无论在体外STAT3磷酸化状态。

靶点

STAT3 ^[1]
(Cell-free assay)

5.1 μM

体外研究

Stattic抑制gp130受体衍生的含磷酸化酪氨酸的肽结合到STAT3 SH2结构域，这种作用存在强烈的温度依赖性。Stattic对酪氨酸磷酸化的肽结合到酪氨酸激酶Lck的SH2结构域只有很微弱的作用效果。Stattic不抑制其他两个二聚体转录因子(c-Myc/Max 和 Jun/Jun)的二聚化。Stattic抑制荧光素标记的磷酸化肽段结合到STAT1和STAT5b的SH2域。Stattic浓度为10 μM，选择性抑制DNA与STAT3二聚体结合。Stattic抑制STAT3在Tyr705位点磷酸化，而对STAT1在Tyr701(HepG2细胞)位点磷酸化或 JAK1, JAK2, 和c-Src(MDA-MB-231和MDA-MB-235S细胞)磷酸化几乎没有抑制效果。Stattic增加STAT3依赖性的乳腺癌细胞系的凋亡率。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
H9c2	MWjGeY5kfGmxbjDBd5NigQ>?	Ml3INVDjiIoQvF2=	NHvUNGc16oDLaB?=		MWny[ZZmenOnczD0bIUh\W[oZXP0d{Bw\iCLTD2yOy=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN\|OU[zN{c,OjZ\|M{m2N\|M9N2F-
NPC	NVz4OJB5TnWwY4Tpc44hSXO\|YYm=	M{PZd\|AuPy53INM1US=>			MVHhZo9tcXOqZYOgSW1VNWyra3WgcY9t\WO3bHHyJIFtfGW{YYTpc45{NCCjbnSgZ4VtdCCvaXfyZZRqd25iYX7kJIlvfmG\|aX;uJIlv\HWlZXSgZpkhWkuLUDDrco9kc2Sxd36=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzNUSzNEc,OjV7MUW0N\|A9N2F-
HASMC	NXK0RXJqTnWwY4Tpc44hSXO\|YYm=	NHjoWFEyNjJ3LUWg{txO	MXmyNEBucW5?	NIPJ[IZFVVORwrC=	M4nzTolvcGmkaYTzJJAuMFlrLWPURXQuOSx\|LEWgd4lodmGuc9Mg	MoS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6NEm2NlIoRjJ3OES5OlIzRC:jPh?=
H9c2	MlL5SpVv[3Srb36gRZN{[Xl?	NXTiXmhGOi9zMDFOwG0>	M{LTOFIhcA>?	NXPvOottTE2VT9Mg	MY\hZpJw\2G2ZYRCpJRp\SCleYTvdJJwfGWldHn2[UBm\m[nY4TzJI9nKEmOLUK3JIFo[Wmwc4SgV2g>	NYrseoF7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NlA6ODdpPkK1PFIxQTB5PD;hQi=>
A431	M3XT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUT5bYVGOsLizszN	NGrPUG4zyqCq		NF;q[lhjdG:la4OgSWdHNXKndnXyd4VlKGSnY4LlZZNmeyCrbjDj[YxtKH[rYXLpcIl1gQ>?	M1rSW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{KwOFM2Lz5{NUeyNFQ{PTxxYU6=
A431	MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVW3eZdROsLizszN	MWCyxsBp		M3HFb4lv[3KnYYPld{BqdiCjcH;weI9{cXNiaX7keYNm\CCkeTDzbIlsd26rbh?=	NGTYdFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyNFQ{PSd-MkW3NlA1OzV:L3G+
SiHa	MonaR4VtdCCYaXHibYxqfHliQYPzZZk>	MXy1MVc2KG6P	NHTN[nczPMLiaNMg		MlXjd4hwf3NibX;ydIhwdG:peTDv[kBiKHS7cHnjZYwh[XCxcITveIlkKGOnbHygZY5lKGSxc3Wt[IVx\W6mZX70JIxwe3Nib3[gZ4VtdCC4aXHibYxqfHoEoB?=	NU\wc3BLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|k3PDRpPkK1OVM6PjR2PD;hQi=>
SiHa	NV65bGt1TnWwY4Tpc44hSXO\|YYm=	M2fQW\|UuPzVibl2=	NXzjZ3lqOjUEoHlCpC=>		MYPy[YR2[2W\|IITo[eKheGixc4Doc5J6dGG2aX;uJIF1KHSqZTD0fZJwe2mwZTDy[ZNq\HWnIEewOeKh	MoLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3M{m2OFQoRjJ3NUO5OlQ1RC:jPh?=
ECA109	M2PRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XV[\|AuOjBizszN	MoT2NlTDqGkEoB?=		NVi1OYlsUUN3ME21MlUxKM7:TR?=	NV3NR\|gyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0PVI1QDBpPkK1OFkzPDhyPD;hQi=>
TE13	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWewMVIxKM7:TR?=	NYfnZXRDOjUEoHlCpC=>		M13NfGlEPTB;Nj6xOeKh\|ryP	MkC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUK0PFAoRjJ3NEmyOFgxRC:jPh?=
KYSE150	M{LHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUSwMVIxKM7:TR?=	NVPwco0xOjUEoHlCpC=>		MnTrTWM2OD1zMj62OOKh\|ryP	NFrlT5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS5NlQ5OCd-MkW0PVI1QDB:L3G+
ECA109	M3jSbWNtd26xZ3XubYMhW3W{dnn2ZYwhSXO\|YYm=	NYr3Zpc6OC53wrFOwG0>	NYj0TY1OOjUEoHlCpC=>		MVnzeZBxemW\|c3XzJJRp\SClbH;uc4dmdmmlIH\vdo1ifGmxbh?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR7MkS4NEc,OjV2OUK0PFA9N2F-
TE13	MoTDR4xwdm:pZX7pZ{BUfXK4aY\hcEBCe3OjeR?=	NIDjSVYxNjYEoN88US=>	MVWyOOKhcMLi		M2L2bpN2eHC{ZYPz[ZMhfGinIHPsc45w\2WwaXOg[o9zdWG2aX;u	M{P5XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEmyOFgxLz5{NUS5NlQ5ODxxYU6=
KYSE150	MlTER4xwdm:pZX7pZ{BUfXK4aY\hcEBCe3OjeR?=	NGi5SIgxNjYEoN88US=>	NFHsfGMzPMLiaNMg		NW\kW\|B7e3WycILld5NmeyC2aHWgZ4xwdm:pZX7pZ{Bnd3KvYYTpc44>	Ml;5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OUK0PFAoRjJ3NEmyOFgxRC:jPh?=
ECA109	NGLP[lNHfW6ldHnvckBCe3OjeR?=	NVXJUXdbOC53wrFOwG0>	NUnsOGtvOjUEoHlCpC=>		MVPlcohidmOnczDJVk1qdmS3Y3XkJIdmdmW{YYTpc44hd2ZiRGPCdy=>	M3;iV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEmyOFgxLz5{NUS5NlQ5ODxxYU6=
PC3M-1E8	MVfGeY5kfGmxbjDBd5NigQ>?	MkfGNk42NzVxMUCg{txO	M1ewdlAuPCCq		NHXNWIJqdmirYnn0d{B1cGViU2TBWFMh[WO2aY\heIlwdiCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XMEoB?=	M2i5c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[xN\|Y2Lz5{NUK2NVM3PTxxYU6=
PC3M-1E8	NFi3UXBHfW6ldHnvckBCe3OjeR?=	NEPvfYwyOCEQvF2=	MUmyOEBp		Mnvl[I94dnKnZ4XsZZRmeyCEY3ytfGwtKHO3co\peolvKGGwZDDjMW16[w>?	M33yTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[xN\|Y2Lz5{NUK2NVM3PTxxYU6=
PC3M-1E8	MnPLSpVv[3Srb36gRZN{[Xl?	NWn6SWRZOTBizszN	M2\zR\|I1KGh?		NGSwTINqdmirYnn0d{BKVC14IHnu[JVk\WRiU2TBWFMh[WO2aY\heIlwdiCjbnSgeIhmKEmOLU[tbY5lfWOnZDDTWGFVOyCjY4TpeoF1cW:w	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4MUO2OUc,OjV{NkGzOlU9N2F-
PC3M-1E8	MU\DcI9vd2enbnnjJHN2en[rdnHsJGF{e2G7	Mk\ZNk42NzVxMUCg{txO			NWrrd3N[cW6qaXLpeJPDqHSqZTDjc4xwdnliZn;ycYF1cW:wIIPp[45q\mmlYX70cJk>	MoTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkGzOlUoRjJ3Mk[xN\|Y2RC:jPh?=
MDA-MB-231	NFXUWGVHfW6ldHnvckBCe3OjeR?=	MornNlAh\|ryP	NFHqXVczKGh?		M1PPXoV5cGmkaYTzJHNv[WmuIHHu[EBGNWOjZHjldolvKGW6cILld5Nqd25?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3M{O0PUc,OjVzNUOzOFk9N2F-
H9c2	M2[1e2Z2dmO2aX;uJGF{e2G7	NIj5elMzOCEEtV2=	MmTPN\|AhdWmw	NGiwSFBFVVORwrC=	NEO4UYNi[m:uaYPo[ZMheHKxcH;mc4wucW6mdXPl[EBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IHLveIghe2W{NEezJIFv\CC2aIKzNFg>	NFewSXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGwOVA3Pyd-MkWxNFUxPjd:L3G+
HaCaT	MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlz5NVAhyrWP	NY\NRXBCOjBibXnu	NIHIPJJFVVORwrC=	MY\lcohidmOnczDzc5Ji\mWwaXKtJIFv\CC\|dX7peIlvcWJvaX7keYNm\CCpcn;3eIghcW6qaXLpeIlwdg>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTBzM{mwO{c,OjVyMUO5NFc9N2F-
Caki-1	M2H1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\2NVAhyrWP	M4rUb\|IxKG2rbh?=	MmHmSG1UV8Li	NHPXbmVmdmijbnPld{B{d3KjZnXubYIuKGGwZDDzeY5qfGmwaXKtbY5lfWOnZDDndo94fGhiaX7obYJqfGmxbh?=	Ml6wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUO5NFcoRjJ3MEGzPVA4RC:jPh?=
HaCaT	MY\BdI9xfG:\|aYOgRZN{[Xl?	NFHvTlEyOCEEtV2=	MkDxNlAhdWmw	NWDHeIQ1TE2VT9Mg	MmLjbY5kemWjc3XzJJBzd3CxcoTpc45{KG:oIHHwc5B1d3SrYzDj[YxteyCmdXWgeI8hfHKnYYTt[Y51KHerdHigd49z[W[nbnniJI9zKHO3bnn0bY5q[g>?	MmG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUO5NFcoRjJ3MEGzPVA4RC:jPh?=
FHL-primed hNSCs	M3nEUWNmdGxiVnnhZoltcXS7IFHzd4F6	NWXoPJFQOC5yMj21JO69VQ>?	NYTReo92PzJiaB?=		NVXrOJFvdGWjZIOgeI8hfGinIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJkh[XRiaHnnbEBkd26lZX70doF1cW:w	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NUSzOEc,OjR7NEW0N\|Q9N2F-
ELL-primed hNSCs	MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MX:wMlAzNTVizszN	MX23NkBp		NFzPbYpt\WGmczD0c{B1cGVibH;zd{Bw\iClZXzsJJZq[WKrbHn0fUBifCCqaXfoJINwdmOnboTyZZRqd25?	M3vvTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS1OFM1Lz5{NEm0OVQ{PDxxYU6=
SS	NEToT5lE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MXyxMVExKM7:TR?=	MnvKO\|IhcA>?	MX7EUXNQ	NIDVbG1k[XW\|ZYOgZUBld3OnLXTldIVv\GWwdDDpcohq[mm2aX;uJI9nKHSqZTD2bYFjcWyrdIpCpC=>	M4r4WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{W2NVEyLz5{NEe1OlEyOTxxYU6=
SeAx	MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M4e4ZVEuOTBizszN	MX:3NkBp	NX3uPGduTE2VTx?=	MVnjZZV{\XNiYTDkc5NmNWSncHXu[IVvfCCrbnjpZol1cW:wIH;mJJRp\SC4aXHibYxqfHoEoB?=	NVqzZm97RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OVYyOTFpPkK0O\|U3OTFzPD;hQi=>
HuT-78	M170OGNmdGxiVnnhZoltcXS7IFHzd4F6	NHHYfJIyNTFyIN88US=>	NUTtUXBlPzJiaB?=	M1vYdWROW09?	NWDHdoJS[2G3c3XzJIEh\G:\|ZT3k[ZBmdmSnboSgbY5pcWKrdHnvckBw\iC2aHWgeoli[mmuaYT5xsA>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd3NkGxNUc,OjR5NU[xNVE9N2F-
CD4+	NVHNU\|lDSXCxcITvd4l{KEG\|c3H5	NVflVHpjOTEkgJpOwI0>	NHP1b4ozPCCq	NUj6OWh3TE2VTx?=	NH;mfVhqdmS3Y3XzJIFxd3C2b4Ppd{B{fHKxbnfsfS=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd3NkGxNUc,OjR5NU[xNVE9N2F-
MCF-7	NWf6fm15T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGn4doIxNjR4OT2zMlc2KM7:TR?=	M2DuNVUh\A>?		NG\2W3Vz\WS3Y3XzJINmdGxiboXtZoVzKHOrZ37p[olk[W62bIm=	MmnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MkiwO\|goRjJ2N{K4NFc5RC:jPh?=
MCF-7/LCC1	M2fWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzk[nAxNjR4OT2zMlc2KM7:TR?=	NGfybHA2KGR?		MUXy[YR2[2W\|IHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{OEC3PEc,OjR5MkiwO\|g9N2F-
MCF-7/LCC9	NF:xeVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLwNE41PjlvMz63OUDPxE1?	NX7oVndGPSCm		M1zWZZJm\HWlZYOgZ4VtdCCwdX3i[ZIhe2mpbnnmbYNidnSueR?=	MkHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MkiwO\|goRjJ2N{K4NFc5RC:jPh?=
HaCaT	NVzvNJZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnwdJhGOTBiwsXN	M37qb\|IxKG2rbh?=	NH\BUlBFVVORwrC=	NUnDVXU5\W6qYX7j[ZMh\X[ncn;sbY12ey2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36=	NVTlc2VwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlMyOzFpPkK0OFI{OTNzPD;hQi=>
HaCaT	MnjFRZBweHSxc3nzJGF{e2G7	NIflO2cyOCEEtV2=	M3z3RVIxKG2rbh?=	MWjEUXNQyqB?	NYDCcmFW\W6qYX7j[ZMhfGinIHHwc5B1d3SrYzDl[oZm[3S\|IH;mJIV3\XKxbHnteZM>	MlOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkOxN\|EoRjJ2NEKzNVMyRC:jPh?=
MDA-MB-231	MmPmSpVv[3Srb36gRZN{[Xl?	M1fiblExKML3TR?=	MYeyOEBp	NYLHcpBtTE2VT9Mg	Mn3JdoVlfWOnczDQMXNVSVR\|IHX4dJJme3Orb36=	NXH2e5FoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzO\|Y2QDZpPkK0N\|c3PTh4PD;hQi=>
SUM-159	MVLGeY5kfGmxbjDBd5NigQ>?	NUK3SYFvOTBiwsXN	MkfzNlQhcA>?	MUjEUXNQyqB?	MUPy[YR2[2W\|IGCtV3RCXDNiZYjwdoV{e2mxbh?=	NWG0fIFMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzO\|Y2QDZpPkK0N\|c3PTh4PD;hQi=>
SK-BR-3	M3LYdGZ2dmO2aX;uJGF{e2G7	M1;lV\|ExKML3TR?=	NWrVWIdSOjRiaB?=	NUHPVo1YTE2VT9Mg	MomxdoVlfWOnczDQMXNVSVR\|IHX4dJJme3Orb36=	MmO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|N{[1PFYoRjJ2M{e2OVg3RC:jPh?=
MCF7-HER2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4S3WlAuOTBizszN	NH6wOoY1QCCq	MVjEUXNQ	NHvsW4lqdmS3Y3XzJINmdGxiZHXheIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	MlizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe1NFgoRjJ2Mkm3OVA5RC:jPh?=
MCF7-HER2	MXTGeY5kfGmxbjDBd5NigQ>?	MVW1JO69VQ>?	MV2yOEBp	Mm[ySG1UVw>?	NYTKT4Y2\GmvaX7pd4hmeyCVb4itNkwhV2O2LUSsJIFv\CC\|bIXnJIV5eHKnc4Ppc44>	M4jJbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3OVA5Lz5{NEK5O\|UxQDxxYU6=
MCF7-HER2	MUnGeY5kfGmxbjDBd5NigQ>?	NVztclhnPSEQvF2=	MUeyOEBp	NV7QSFV6TE2VTx?=	NGnvbZNl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wy\|IH;mJGVOXCCvYYLr[ZJ{NCC4aX3lcpRqdiCjbnSgd4x2\w>?	M1LTfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3OVA5Lz5{NEK5O\|UxQDxxYU6=
MCF7-HER2	NEDZcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFS1dI42KM7:TR?=	NH6xSXMzPCCq	MkDPSG1UVw>?	NIK4PHVmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIHPvcYJqdmWmIIfpeIghUGW{Y3XweIlv	Ml34QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe1NFgoRjJ2Mkm3OVA5RC:jPh?=
HMECs	NIm3RZZHfW6ldHnvckBCe3OjeR?=	M2\ycFExKM7:TR?=	NYXrfGtvOiCq		NHKwVI5qdmirYnn0d{BKTk8QsdMgcYVlcWG2ZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJHNVSVRzLDDTWGFVOiCjbnSgV3RCXDN?	NIHJR2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEKxNVMzPyd-MkSyNVE{Ojd:L3G+
HTR8/SVneo	NUDsNZR7TnWwY4Tpc44hSXO\|YYm=	MUGxxsDPxE4EoB?=	MoPUNeKhcA>?		NHnWSml{fXCycnXzd4VlKE:VTT3pcoR2[2WmIGPURXQ{KHCqb4PwbI9zgWyjdHnvci=>	NWfkUmRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOlAzPDFpPkK0NFYxOjRzPD;hQi=>
HTR8/SVneo	M4jCWWZ2dmO2aX;uJGF{e2G7	NYP5T4JqOC53L{JCpO69VcLi	M3e4[\|Q5KGh?		MUXy[ZN1d3KnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJJN2eHC{ZYPz[YQh[nliT2PN	NFTNbVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2NFI1OSd-MkSwOlAzPDF:L3G+
HTR8/SVneo	MnLISpVv[3Srb36gRZN{[Xl?	Mmj0NeKh\|ryPwrC=	NUXBPVFpPDhiaB?=		MWTzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCvaXfyZZRqd25iYomgU3NOyqB?	NXL3clI3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOlAzPDFpPkK0NFYxOjRzPD;hQi=>
C13*	MYfBdI9xfG:\|aYOgRZN{[Xl?	M1XSOVAuOTBizszN	NV3KUI9WOjRxNEigbC=>		Mln3bY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4MkW1PEc,OjN7NkK1OVg9N2F-
OV2008	M1vEdGFxd3C2b4Ppd{BCe3OjeR?=	M2LnelAuOTBizszN	NWn4VFR6OjRxNEigbC=>		NHniU3dqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4MkW1PEc,OjN7NkK1OVg9N2F-
C13*	NIP3fmZCeG:ydH;zbZMhSXO\|YYm=		NXTjPGdNOjRxNEigbC=>		M1v5cIVvcGGwY3XzJINqe3CuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MojvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkK1OVgoRjJ\|OU[yOVU5RC:jPh?=
OV2008	MXHBdI9xfG:\|aYOgRZN{[Xl?		NUPWeo5WOjRxNEigbC=>		NFTBV3NmdmijbnPld{BkcXOybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4MkW1PEc,OjN7NkK1OVg9N2F-
W480	M1PxTWZ2dmO2aX;uJGF{e2G7	M1\0flIvPS9zMDFOwG0>	MmC3N\|AhdWmw	M{fNdmROW09?	MXfz[Y5{cXSrenXzJINmdGy\|IITvJINp\W2xcnHkbY91cGW{YYD5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NVu0RXRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|Q6PzJpPkKzPVM1QTd{PD;hQi=>
SW837	M1jURmZ2dmO2aX;uJGF{e2G7	NYHOflFrOi53L{GwJO69VQ>?	M{fvfVMxKG2rbh?=	NE\RdpVFVVOR	MUfz[Y5{cXSrenXzJINmdGy\|IITvJINp\W2xcnHkbY91cGW{YYD5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl\|NEm3Nkc,OjN7M{S5O\|I9N2F-
T24	MWDGeY5kfGmxbjDBd5NigQ>?	M1XvSFIwOTBxMkCg{txO	NHf6XGgzPCCq		M1XYXINifXOnczDkc5NmNWSncHXu[IVvfCCrbnjpZol1cW:wIH;mJJRp\SCFWFPMNVIucW6mdXPl[EBqdmO{ZXHz[UBw\iCrbo\h[Ilv\yClZXzsdy=>	MojNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3Mk[wO\|koRjJ\|NUK2NFc6RC:jPh?=
CNE1	MVXGeY5kfGmxbjDBd5NigQ>?	MlXaNlAhyrWP	MmnBOFghcA>?		MVLicI9kc3NidHjlJGlNNTZiaX7jdoVie2WmIIDoc5NxcG:{eXzheIlwdiCxZjDTeIF1Ow>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
CNE2	NGXVW2RHfW6ldHnvckBCe3OjeR?=	NI[5OpMzOCEEtV2=	MoDqOFghcA>?		NVfCbJBE[myxY3vzJJRp\SCLTD22JIlv[3KnYYPl[EBxcG:\|cHjvdplt[XSrb36gc4YhW3SjdEO=	M3jHbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
HONE1	NIfnelVHfW6ldHnvckBCe3OjeR?=	MWeyNEDDvU1?	MWG0PEBp		NUXpO4ZD[myxY3vzJJRp\SCLTD22JIlv[3KnYYPl[EBxcG:\|cHjvdplt[XSrb36gc4YhW3SjdEO=	MkXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OEK5NVQoRjJ\|M{iyPVE1RC:jPh?=
CNE1	Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7Ed5FkPCEQvF2=			MXrzbYdvcW[rY3HueIx6KHKnZIXj[ZMh[2WubDD2bYFjcWyrdIm=	M1P6T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
CNE1	NWP1Too4TnWwY4Tpc44hSXO\|YYm=	MX2wMVIxKM7:TR?=	Mor3NE01KGh?		MXLpcohq[mm2czDTeIF1OyCjY4TpeoF1cW:wIHnuJIEh\G:\|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	M4PnbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
CNE2	M1z2b2Z2dmO2aX;uJGF{e2G7	NXfFXG1TOC1{MDFOwG0>	MXGwMVQhcA>?		NVrIOWExcW6qaXLpeJMhW3SjdEOgZYN1cX[jdHnvckBqdiCjIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	NYr5bJhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFI6OTRpPkKzN\|gzQTF2PD;hQi=>
HONE1	NGX2TFVHfW6ldHnvckBCe3OjeR?=	NFHFU40xNTJyIN88US=>	M1vk[FAuPCCq		NEXsOpdqdmirYnn0d{BUfGG2MzDhZ5RqfmG2aX;uJIlvKGFiZH;z[U0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
CNE1	MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NG\rdmsxNjVvNkSg{txO	NEP5UlE1QCCq		Mm\rd5VxeHKnc4Pld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK=	NH;XTI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O4NlkyPCd-MkOzPFI6OTR:L3G+
CNE2	MmD6R4VtdCCYaXHibYxqfHliQYPzZZk>	M2OzZVAvPS14NDFOwG0>	NGTKT2Q1QCCq		NX7aUJNDe3WycILld5NmeyClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
HONE1	M{HETmNmdGxiVnnhZoltcXS7IFHzd4F6	M2XpUVAvPS14NDFOwG0>	MmD2OFghcA>?		MonEd5VxeHKnc4Pld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK=	NVrwc2NyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFI6OTRpPkKzN\|gzQTF2PD;hQi=>
C666-1	NHnQZW1E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NF\TT4ExNjVvNkSg{txO	M17xbFQ5KGh?		MXnzeZBxemW\|c3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	Mn\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|OEK5NVQoRjJ\|M{iyPVE1RC:jPh?=
CNE1	MX7BdI9xfG:\|aYOgRZN{[Xl?	M2rXOVExKML3TdMg	MlrhOFghcA>?		NI[1eJJqdmS3Y3XzJIFxd3C2b4Ppd:Kh	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6MkmxOEc,OjN\|OEK5NVQ9N2F-
CNE2	M2XBe2Fxd3C2b4Ppd{BCe3OjeR?=	NEHveGoyOCEEtV5CpC=>	MkT2OFghcA>?		NY\Bc3BvcW6mdXPld{BieG:ydH;zbZPDqA>?	NVnDXZN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFI6OTRpPkKzN\|gzQTF2PD;hQi=>
HONE1	MnX4RZBweHSxc3nzJGF{e2G7	NH\jPVMyOCEEtV5CpC=>	NVHLXG06PDhiaB?=		MnfLbY5lfWOnczDhdI9xfG:\|aYRCpC=>	NYXvc2lxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFI6OTRpPkKzN\|gzQTF2PD;hQi=>
CNE2	NETYbFBE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MX[xM\|Ih\|ryP	NYf0VYNRPDhiaB?=		MoHFd4Vve2m2aYrlJINmdGy\|IITvJJJi\GmxdHjldoFxgQ>?	NWe1OJZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFI6OTRpPkKzN\|gzQTF2PD;hQi=>
HONE1	NGXNXFhE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MVqxM\|Ih\|ryP	Mn\6OFghcA>?		MnjNd4Vve2m2aYrlJINmdGy\|IITvJJJi\GmxdHjldoFxgQ>?	NETtdWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O4NlkyPCd-MkOzPFI6OTR:L3G+
C666-1	MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M1Pi[FEwOiEQvF2=	NHTJPHc1QCCq		M3TVXpNmdnOrdHn6[UBk\WyuczD0c{Bz[WSrb4To[ZJieHl?	M3LuRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{iyPVE1Lz5{M{O4NlkyPDxxYU6=
HEC-1A	NGPZUWVHfW6ldHnvckBCe3OjeR?=	M33zd\|HDqM7:TdMg	M{i0dlI1KGh?	MYXEUXNQ	MX7icI9kc3NidHjlJG1WSzJyLXXubIFv[2WmIHnueoF{cW:wIITybYdo\XKnZDDifUAyOCViRlLT	NXS0bGFYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOlIzODhpPkKzNlYzOjB6PD;hQi=>
RL95-2	NV7ZS5Y6TnWwY4Tpc44hSXO\|YYm=	NH7jemsyyqEQvF5CpC=>	Mkm4NlQhcA>?	NXfxZ3kxTE2VTx?=	NHLPfmVjdG:la4OgeIhmKE2XQ{KwMYVvcGGwY3XkJIlvfmG\|aX;uJJRzcWepZYLl[EBjgSBzMDWgSmJU	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ4MkKwPEc,OjN{NkKyNFg9N2F-
HEC-1A	M{PZNmZ2dmO2aX;uJGF{e2G7	Mnn3NeKh\|ryPwrC=	MlXFNlQhcA>?	NUPYelZOTE2VTx?=	M1fsOYJtd2OtczD0bIUhVVWFMkCt[Y5p[W6lZXSgbY53[XOrb36geJJq\2encnXkJIJ6KEWJRtMg	NFfDT4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K2NlIxQCd-MkOyOlIzODh:L3G+
RL95-2	MV\GeY5kfGmxbjDBd5NigQ>?	NGjjeoIyyqEQvF5CpC=>	MnLSNlQhcA>?	NInnOGRFVVOR	M3jYSIJtd2OtczD0bIUhVVWFMkCt[Y5p[W6lZXSgbY53[XOrb36geJJq\2encnXkJIJ6KEWJRtMg	NWjZWlhVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOlIzODhpPkKzNlYzOjB6PD;hQi=>
CT26	NE\mTnlHfW6ldHnvckBCe3OjeR?=	M2HXbVIxKG2P	NFL0UVMyKGh?		M3XNbpN2eHC{ZYPz[ZMhUEeILXnu[JVk\WRiVlXHSkBmgHC{ZYPzbY9vyqB?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ\|M{G2N{c,OjN{M{OxOlM9N2F-
UM-SCC-17B	M{P5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXnScppHUUN3ME2yMlU3OiEEsTCwMlQxQSEQvF2sJGdKPTB;MT6yO\|khyrFiMD6xPVQh\|ryP	M4noXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ewPFk6Lz5{Mke3NFg6QTxxYU6=
OSC-19	NIfKTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXQTWM2OD1\|LkS4NUDDuSByLkm1N{DPxE1uIFfJOVA:OS5\|Nk[gxtEhOC55N{Cg{txO	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd5MEi5PUc,OjJ5N{C4PVk9N2F-
Cal33	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTJwMkiyJOKyKDBwNEKzJO69VSxiR1m1NF0yNjN2OTFCtUAxNjN4MzFOwG0>	NHfJU409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFg6QSd-MkK3O\|A5QTl:L3G+
UM-SCC-22B	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnDNGxKSzVyPUKuOlQ5KMLzIECuOVQzKM7:TTygS2k2OD1zLkOyNEDDuSByLkKwOEDPxE1?	M1LzPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ewPFk6Lz5{Mke3NFg6QTxxYU6=
UM-SCC-17B	MXPGeY5kfGmxbjDBd5NigQ>?	M37QTlAuOzBizszN	M3LuSVAuOjRiaB?=		MV7pcohq[mm2czDTWGFVOyCjY4TpeoF1cW:wIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl?	NW\HeI1{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3O\|A5QTlpPkKyO\|cxQDl7PD;hQi=>
OSC-19	MX7GeY5kfGmxbjDBd5NigQ>?	NVP1SZRTOC1\|MDFOwG0>	NYXMfYhUOC1{NDDo		M1TDZYlvcGmkaYTzJHNVSVR\|IHHjeIl3[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?=	NIjKSpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFg6QSd-MkK3O\|A5QTl:L3G+
Cal33	MoXZSpVv[3Srb36gRZN{[Xl?	NFrLRYcxNTNyIN88US=>	MoPJNE0zPCCq		NHvFRVJqdmirYnn0d{BUXEGWMzDhZ5RqfmG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm=	M3nQRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ewPFk6Lz5{Mke3NFg6QTxxYU6=
UM-SCC-22B	MlfNSpVv[3Srb36gRZN{[Xl?	NXXHRXlUOC1\|MDFOwG0>	NF3CSVgxNTJ2IHi=		NV[yN2ZncW6qaXLpeJMhW1SDVEOgZYN1cX[jdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd5MEi5PUc,OjJ5N{C4PVk9N2F-
U-87MG	MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M{\rTVAuOTBizszN	M{n6dVczKGh?	NUS2O5FiTE2VTx?=	NIX1eo5qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	NYPROWxjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N\|Y3QDJpPkK1OFM3Pjh{PD;hQi=>
U-373MG	M3LVVmNmdGxiVnnhZoltcXS7IFHzd4F6	MWiwMVExKM7:TR?=	M{L5cFczKGh?	NEnQZpJFVVOR	MlW0bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MnvwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{[2PFIoRjJ3NEO2OlgzRC:jPh?=
SH-SY5Y	NEizR2tE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M{DQc\|AuOTBizszN	M3f6eFczKGh?	NX3C[XR{TE2VTx?=	NFnNdW9qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	M2fu[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEO2OlgzLz5{NUSzOlY5OjxxYU6=
Tu-9648	NIrPRmFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MoX0NE0yOCEQvF2=	NVLLO3BGPzJiaB?=	M2\1fGROW09?	NV32NmNbcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	NH;pcGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzOlY5Oid-MkW0N\|Y3QDJ:L3G+
Neuro-2a	M{XuSWNmdGxiVnnhZoltcXS7IFHzd4F6	MVewMVExKM7:TR?=	NGDCS444OiCq	NFy5b3NFVVOR	M3Kw[YlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	MlO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{[2PFIoRjJ3NEO2OlgzRC:jPh?=
PCNs	NUDEXJBCS2WubDDWbYFjcWyrdImgRZN{[Xl?	Mm\VNE0yOCEQvF2=	NX;uemdIPzJiaB?=	NVrNdHVJTE2VTx?=	NEPTOmpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	NHK1Oo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzOlY5Oid-MkW0N\|Y3QDJ:L3G+
PGCs	MmLzR4VtdCCYaXHibYxqfHliQYPzZZk>	NYXLb25iOC1zMDFOwG0>	NVniSHU2PzJiaB?=	M1vrfWROW09?	M1zoTIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	NWfEeHlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N\|Y3QDJpPkK1OFM3Pjh{PD;hQi=>
RAW264.7	MoTQSpVv[3Srb36gRZN{[Xl?	M3\Z[lExKM7:TR?=	NVjNdZhVOTJiaB?=		M1TyZoFjem:pYYTld{B1cGVibWLORUBmgHC{ZYPzbY9veyCxZjDKRWszNCCVVFHUNUwhW1SDVEKsJIFv\CCVVFHUN{BqdmS3Y3XkJIJ6KESRTjDhcoQhXC1{IITvfIlv	NWP2VmNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OVQ1OzFpPkKyOFU1PDNzPD;hQi=>
RAW264.7	MV3BdI9xfG:\|aYOgRZN{[Xl?	NYP2WGFyPS9zMDFOwG0>	MnPhOFUhdWmw		MWXlcohidmOnczD0c5hqdnNiaX7keYNm\CCjcH;weI9{cXNiYX7kJG1OWCCub4Pz	NYPM[WZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OVQ1OzFpPkKyOFU1PDNzPD;hQi=>
SW480	MnjqR4VtdCCYaXHibYxqfHliQYPzZZk>	M1TJUFUwOTBxMkCg{txO	NFzpd\|E4OiCq		MnnBbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlib3[geIhmKEGORFirM2NFOTN\|K9MgZ4VtdHN?	M2DId\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUCwN\|k4Lz5{MUmwNFM6PzxxYU6=
HCT116	NYXjUlB1S2WubDDWbYFjcWyrdImgRZN{[Xl?	M1HDTVUwOTBxMkCg{txO	NYfreGU4PzJiaB?=		Mo[ybY5pcWKrdIOgZ4VtdCC4aXHibYxqfHlib3[geIhmKEGORFirM2NFOTN\|K9MgZ4VtdHN?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTlyMEO5O{c,OjF7MECzPVc9N2F-
DLD-1	M1LTXWNmdGxiVnnhZoltcXS7IFHzd4F6	MX61M\|ExNzJyIN88US=>	MnW0O\|IhcA>?		NH7KbpVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDv[kB1cGViQVzETEswS0RzM{OrxsBk\Wyucx?=	NGPkR4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmwNFM6Pyd-MkG5NFA{QTd:L3G+
SNU387	MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NIXxSpEzOMLizszNxsA>	MmC2NlQhcA>?		MorydoVlfWOnczDj[YxtKH[rYXLpcIl1gQ>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTNzMUm3OUc,OjF\|MUG5O\|U9N2F-
SNU398	MkHnR4VtdCCYaXHibYxqfHliQYPzZZk>	MlLGNlDDqM7:TdMg	NXHUe5I3OjRiaB?=		M3K0SZJm\HWlZYOgZ4VtdCC4aXHibYxqfHl?	NUTjNWlQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzNVE6PzVpPkKxN\|EyQTd3PD;hQi=>
HepG2	M1[2UGNmdGxiVnnhZoltcXS7IFHzd4F6	M{nR[FIxyqEQvF5CpC=>	MW[yOEBp		NUOzO2J4emWmdXPld{Bk\WyuII\pZYJqdGm2eR?=	Mmr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|MUG5O\|UoRjJzM{GxPVc2RC:jPh?=
Huh-7	MoXvR4VtdCCYaXHibYxqfHliQYPzZZk>	MnLMNlDDqM7:TdMg	M1zEcVI1KGh?		NHz1[VVz\WS3Y3XzJINmdGxidnnhZoltcXS7	MoPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|MUG5O\|UoRjJzM{GxPVc2RC:jPh?=
VSMC	MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnr3N{82NzFyIN88US=>	MoG3N\|AhdWmw	NX3KOpNxTE2VTx?=	NHjRZm1xemW4ZX70d{BRTEeILTDhcoQhfGi{b33ibY4udWWmaXH0[YQhXlOPQzDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh2N{OwOkc,OjB6NEezNFY9N2F-
MDA-MB-231	MlXDRZBweHSxc3nzJGF{e2G7	M3HCOFExKM7:TR?=	Mmm0NlQhcA>?	MlfQSG1UV8Li	NG\pbYpqdmS3Y3XzJIFxd3C2b4Ppdy=>	NWHkOmJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexNVQxODVpPkG3NVE1ODB3PD;hQi=>
MDA-MB-435S	M4jrbmFxd3C2b4Ppd{BCe3OjeR?=	MojINVAh\|ryP	NGr2RXozPCCq	NHHLbJVFVVORwrC=	NYD0O3c{cW6mdXPld{BieG:ydH;zbZM>	NGLERXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GxOFAxPSd-MUexNVQxODV:L3G+
AsPC1	NFzibIVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVHjOlNUPzJiaILz		NXvreZZMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBd3BEOSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNU4{OiEQvF2u	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyNEm2Okc,OjR7MES5OlY9N2F-
MDA-MB-231	M3HjfmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M{XwNFczKGi{cx?=		M2TGSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSXIudmWpYYTpeoUh[W6mIITybZBt\S2wZXfheIl3\SCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGlEPTBiPTCyMlg6KM7:TT6=	NEC2c2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwOFk3Pid-MkS5NFQ6PjZ:L3G+
MCF7	M4XpPGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVe3NkBpenN?		NEPibplCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGVTNXCxc3n0bZZmKGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFMvPiEQvF2u	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyNEm2Okc,OjR7MES5OlY9N2F-
PANC1	NWryUoRHSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MUe3NkBpenN?		NH3vdWZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDBUmMyKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGlEPTBiPTCzMlc4KM7:TT6=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyNEm2Okc,OjR7MES5OlY9N2F-
MDA-MB-231	NEi1UHZEgXSxdH;4bYNqfHliYYPzZZk>		M3Hu[VQ5KGi{cx?=		M1;IVGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFEvPTZizszNMi=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7Nk[4PUc,OjZ\|OU[2PFk9N2F-
MDA-MB-435S	MlPXR5l1d3SxeHnjbZR6KGG\|c3H5		NHe2d5E1QCCqcoO=		MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1V{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNU45PyEQvF2u	M4PrRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m2Olg6Lz5{NkO5OlY5QTxxYU6=
MCF7	MYfDfZRwfG:6aXPpeJkh[XO\|YYm=		M3nHclQ5KGi{cx?=		M{XpfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJwMU[g{txONg>?	NWL4R4hJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVY3QDlpPkK2N\|k3Pjh7PD;hQi=>
A549	M1HvbWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MWW0PEBpenN?		M4D6SWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJwNTFOwG0v	NYXzSII5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVY3QDlpPkK2N\|k3Pjh7PD;hQi=>
DU145	M2D6SmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M4\i[VQ5KGi{cx?=		MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOi53IN88UU4>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7Nk[4PUc,OjZ\|OU[2PFk9N2F-
PANC1	NVnhcnpKS3m2b4TvfIlkcXS7IHHzd4F6		MXO0PEBpenN?		NWPMeZJrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEGQQ{GgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuPUDPxE1w	NF7R[pM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5OlY5QSd-Mk[zPVY3QDl:L3G+
HCT116	MV;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MYC3NkBpenN?		MnLiRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuNFgh\|ryPLh?=	M4LWdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{G4OFcxLz5{N{exPFQ4ODxxYU6=
MDA-MB-231	MV7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4\wOVczKGi{cx?=		NI\JdpBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwNkig{txONg>?	NWT5coMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3NVg1PzBpPkK3O\|E5PDdyPD;hQi=>
MCF7	NF7lb3NCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NU\RbJVSPzJiaILz		MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJwM{[g{txONg>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzdzOES3NEc,Ojd5MUi0O\|A9N2F-
A549	MkjFRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NYrncFF4PzJiaILz		NH7sRXZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IESuOEDPxE1w	MkTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5MUi0O\|AoRjJ5N{G4OFcxRC:jPh?=
AD293	MVvGeY5kfGmxbjDhd5NigQ>?		MYW2JIhzew>?		MXfJcohq[mm2aX;uJI9nKEmITnfhcY1iNXO2aX31cIF1\WRiR1\QM2ZNSUdvdHHn[4VlKFOWQWSzJIRqdWW{aYrheIlwdiCrbjDoeY1idiCDREK5N{Bk\WyuczDpcoN2[mG2ZXSg[o9zKDZiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrczygTWM2OCB;IEWuNUDPxE1w	NYr0XXhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNlgxODBpPkOwNlI5ODByPD;hQi=>
MDA-MB-231	M4DtdWZ2dmO2aX;uJIF{e2G7	NEHWTowyKHSxIEGwJJVO	NITQSWQyOiCqcoO=		MmjSTY5pcWKrdHnvckBw\iCVVFHUN{BxcG:\|cHjvdplt[XSrb36gZZQhXHm{N{C1JIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZQhOSC2bzCxNEB2VSCjZoTldkAyOiCqcoOgZpkhf2W\|dHXyckBjdG:2IHHuZYx6e2m\|	MoHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MES5OlYoRjJ2OUC0PVY3RC:jPh?=
MDA-MB-231	NYGxW4tRSW62aXPhcoNmeiCjc4PhfS=>	M33ReVEhfG9iMUCgeW0>	MoXzOFghcHK\|		Mk\0RY51cWOjbnPldkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdixiYYDvdJRwe2m\|IHHu[EBk\WyudXzhdkBud3KyaH;sc4dq[2GuIHPoZY5o\XNiYYSgNUB1dyBzMDD1UUBi\nSncjC0PEBpenNiYomgcIlocHRibXnjdo9{[2:yeR?=	NFO2UVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwOFk3Pid-MkS5NFQ6PjZ:L3G+
MDA-MB-231	MXHGeY5kfGmxbjDhd5NigQ>?	MVWxJJRwKDFyIIXN	Ml65NVIhcHK\|		Mm\NSIVkemWjc3WgbY4hW1SDVEOgdJJwfGWrbjDlfJBz\XO\|aX;uJIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZQhOSC2bzCxNEB2VSCjZoTldkAyOiCqcoOgZpkhf2W\|dHXyckBjdG:2IHHuZYx6e2m\|	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyNEm2Okc,OjR7MES5OlY9N2F-
MCF7	MX;GeY5kfGmxbjDhd5NigQ>?		M2\sVVEzKGi{cx?=		MUjJcohq[mm2aX;uJI9nKFOWQWSzJJBpd3OyaH;yfYxifGmxbjDheEB[PzB3IHnuJIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiMUKgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NE\HSoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5OlY5QSd-Mk[zPVY3QDl:L3G+
MDA-MB-435S	NVTyW29GTnWwY4Tpc44h[XO\|YYm=		M4rOPVEzKGi{cx?=		NYPSTmtbUW6qaXLpeIlwdiCxZjDTWGFVOyCyaH;zdIhwenmuYYTpc44h[XRiWUewOUBqdiCqdX3hckBOTEFvTVKtOFM2WyClZXzsd{Bi\nSncjCxNkBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	M1rTZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m2Olg6Lz5{NkO5OlY5QTxxYU6=
MDA-MB-231	M3LwemZ2dmO2aX;uJIF{e2G7		NICwN3oyOiCqcoO=		NETwboNKdmirYnn0bY9vKG:oIGPURXQ{KHCqb4PwbI9zgWyjdHnvckBifCC\N{C1JIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZYZ1\XJiMUKgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NGjvdJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5OlY5QSd-Mk[zPVY3QDl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-STAT3 / STAT3 ; PubMed: 25261365 Oncotarget (A) PC3M-1E8 cells were treated with different doses of Stattic for 4 h. (B) PC3M-1E8 cells were treated with 10 μM Stattic for different time points. Survivin / c-Myc / Bcl-xl ; PubMed: 25261365 Oncotarget Western blot analysis of STAT3 downstream targets in PC3M-1E8 cells treated with 10 μM Stattic for 24 h. PARP / C-PARP / Caspase-3 / C-Caspse-3 ; PubMed: 23382914 PLoS One NPC cells were exposed to the indicated concentrations of Stattic for 48 h; apoptotic cells were measured by western blot analysis of cleaved PARP and cleaved caspase-3. Protein levels were quantified using ImageJ software.	25261365 23382914
Immunofluorescence	p-STAT3 / STAT3 / Survivin ; PubMed: 25261365 Oncotarget Cellular localization of pSTAT3 and survivin (green) was observed by confocal microscopy after immunofluorescent staining of PC3M-1E8 cancer cells treated with 10 μM Stattic.	25261365
Growth inhibition assay	Cell viability; PubMed: 23382914 PLoS One Stattic inhibits the cell viability of NPC cells in a time-dependent manner. CNE2 cells were treated with 8 µM Stattic for the indicated times, and cell viability was measured by the MTT assay.	23382914
ELISA	BDNF; PubMed: 27456333 Sci Rep BDNF secretion was analyzed using ELISA in A549 and H1299 cells treated with or without Stattic. Results are shown as the mean ± S.E. n = 3; *p < 0.05, vs Control group, Student’s t-test.	27456333

激酶实验： ^[1]	- 合并高通量筛选和荧光偏振检测: 在约30°C下进行筛选。通过实验化合物与STAT1, STAT5, 和 Lck 的SH2结构域结合的类似实验验证筛选的特异性。所有FP实验的Buffer组分的终浓度为10 mM HEPES(pH 7.5),1 mM EDTA,0.1% Nonidet P-40,50 mM NaCl,和10% DMSO。二硫苏糖醇的存在对抑制活性是必不可少的。肽序列为:STAT3,5-carboxyfluorescein-GY(PO₃H₂)LPQTV-NH2; STAT1, 5-carboxyfluorescein-GY(PO₃H₂)DKPHVL;STAT5, 5-carboxyfluorescein-GY(PO₃H₂)LVLDKW; 和 Lck, 5-carboxyfluorescein-GY(PO₃H₂)EEIP。在 30°C下进行特异性分析, 使用150 nM蛋白(STAT1,STAT3,和STAT5)。在37°C下进行分析，使用370 nM 蛋白(STAT3)或100 nM蛋白 (Lck)。蛋白与实验化合物在Eppendorf管中在指定温度环境下温育60分钟，然后加入相应的5-carboxyfluorescein标记的肽（终浓度为10 nM）。混合物至少平衡30分钟，然后在室温下测量。实验化合物在20×stock在DMSO中稀释到指定浓度。使用 SigmaPlot绘制结合曲线和抑制曲线。独立实验中，所有竞争曲线都需重复三次。
细胞实验： ^[2]	- 合并 Cell lines: Ly3细胞 Concentrations: ~2.5 μM Incubation Time: 48小时 Method: MTS (Only for Reference)
动物实验： ^[2]	- 合并 Animal Models: Ly3亲本NOD/SCID IL2R移植瘤 Dosages: 每天3.75 mg/kg Administration: 瘤内注射 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	42 mg/mL (198.87 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O	10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Stattic SDF

分子量	211.19
化学式	C₈H₅NO₄S
CAS号	19983-44-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
We need to dissolve the compound for i.p. injection, could you give me some suggestions?
回答：
S7024 Stattic can be dissolved in 2% DMSO/PEG 300/dd H2O at 8 mg/mL as a clear solution.

研究领域

产品类型

定制您的化合物库

Stattic

客户使用Selleck生产的Stattic发表文献153篇：

产品安全说明书

STAT抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Stattic SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

STAT Signaling Pathway Map

相关STAT产品